New Drug Causes 20 Percent Weight Loss in Early Amgen Results
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 percent of their weight in a year. The drug, MariTide, is given by injection once a month, compared with once a week for other obesity drugs like Wegovy and Zepbound that are already on the market.
The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...
MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...
The Wall Street Journal on MSN3h
Eli Lilly and Novo Nordisk’s Obesity Moat Just Got StrongerData from their most serious competitor, Amgen, suggests the biotech won’t upstage the market leaders.
Key TakeawaysA Phase 2 study of Amgen's experimental weight-loss treatment didn't meet expectations of analysts.Concerns were ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback